H 021
Alternative Names: H-021Latest Information Update: 04 Nov 2024
Price :
$50 *
At a glance
- Originator Jiangsu Carephar Pharmaceutical
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ulcerative colitis
Most Recent Events
- 17 Sep 2024 Phase-I clinical trials in Ulcerative colitis (In volunteers) in Australia (PO) (NCT06627556)